[Business Highlights and Near-Term Milestones](index=1&type=section&id=Business%20Highlights%20and%20Near-Term%20Milestones) NextCure updated on NC410 and LNCB74 clinical programs, with NC410 Phase 1b data at ASCO and LNCB74 IND submission planned by year-end, supported by **$96.0 million** cash into H2 2026 - The company's cash reserves of approximately **$96.0 million** are projected to fund operations into the second half of 2026[5](index=5&type=chunk) [NC410 (LAIR-2 fusion)](index=1&type=section&id=NC410%20%28LAIR-2%20fusion%29) - Clinical data from the Phase 1b study of NC410 in combination with pembrolizumab for colorectal (CRC) and ovarian cancer will be presented at the ASCO Annual Meeting on June 1, 2024[5](index=5&type=chunk)[6](index=6&type=chunk) - The ASCO presentation will include data from an additional **20 CRC patients** enrolled in the **100 mg cohort** in January 2024[6](index=6&type=chunk) - Enrollment of additional ovarian cancer patients began in March 2024, with data anticipated in the second half of 2024[6](index=6&type=chunk) [LNCB74 (B7-H4 ADC)](index=1&type=section&id=LNCB74%20%28B7-H4%20ADC%29) - An Investigational New Drug (IND) application for LNCB74 is planned for submission by the end of 2024[3](index=3&type=chunk)[6](index=6&type=chunk) - Preclinical data presented at the 2024 AACR Annual Meeting highlighted strong safety and pharmacokinetic profiles for LNCB74[6](index=6&type=chunk) - GLP toxicology studies have been initiated, and production of clinical material has commenced with collaborator LigaChem Biosciences[3](index=3&type=chunk)[6](index=6&type=chunk) [Financial Results for Quarter Ended March 31, 2024](index=2&type=section&id=Financial%20Results%20for%20Quarter%20Ended%20March%2031%2C%202024) NextCure reported a **net loss of $17.1 million** for Q1 2024, with cash at **$96.0 million**, stable R&D, reduced G&A, and **$2.5 million** in restructuring costs [Financial Performance Summary](index=2&type=section&id=Financial%20Performance%20Summary) Financial Performance Summary (in millions) | Financial Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | **Cash, Cash Equivalents, and Marketable Securities** | $96.0 | - | | **Research and Development Expenses** | $11.4 | $11.6 | | **General and Administrative Expenses** | $4.4 | $5.4 | | **Restructuring and Asset Impairment Costs** | $2.5 | $0 | | **Net Loss** | $17.1 | $16.1 | - The decrease in cash of **$12.3 million** from year-end 2023 was primarily due to cash used to fund operations[10](index=10&type=chunk) - The decrease in G&A expenses was primarily related to lower personnel-related costs and lower insurance costs[10](index=10&type=chunk) [Selected Financial Information](index=4&type=section&id=Selected%20Financial%20Information) Selected Statement of Operations Items (in thousands) | Item | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Research and development | $11,398 | $11,647 | | General and administrative | $4,364 | $5,424 | | Restructuring and asset impairment | $2,542 | - | | **Loss from operations** | **($18,304)** | **($17,071)** | | Other income, net | $1,197 | $975 | | **Net loss** | **($17,107)** | **($16,096)** | | **Net loss per common share** | **($0.61)** | **($0.58)** | Selected Balance Sheet Items (in thousands) | Item | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents, and marketable securities | $96,001 | $108,299 | | Total assets | $115,159 | $128,038 | | Total stockholders' equity | $99,048 | $114,421 | [Corporate Information](index=2&type=section&id=Corporate%20Information) This section outlines NextCure's mission for cancer therapies and includes a safe harbor statement on forward-looking statements and risks [About NextCure, Inc.](index=2&type=section&id=About%20NextCure%2C%20Inc.) - NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines for cancer patients who do not respond to, or have disease progression on, current therapies[8](index=8&type=chunk) - The company utilizes differentiated mechanisms of action, including antibody-drug conjugates and antibodies, leveraging its expertise in biological pathways and the tumor microenvironment[8](index=8&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) - The press release contains forward-looking statements concerning the company's financial runway, clinical trial progress, development plans, and upcoming milestones[9](index=9&type=chunk) - Identified risks and uncertainties include the unpredictability of preclinical results in clinical trials, limited operating history, history of significant losses, and the need to obtain additional financing[11](index=11&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38905 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 47-5231247 (State or other ...

Mr. Richman continued, "We are excited to focus on NC410 combo, which is demonstrating clinical responses in ovarian and colorectal cancers. We are advancing LNCB74 in collaboration with LegoChem Biosciences, a differentiated ADC directed to B7-H4, a clinically validated cancer target. Given our current cash position and revised runway to the second half of 2026, we believe we can advance our two programs through important near-term clinical milestones." Business Highlights and Near-Term Milestones Prioriti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38905 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 47-5231247 (State ...

(Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38905 NextCure, Inc. (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identif ...

✓ 5 dose cohorts: 0.5 – 20 mg/kg · Phase 1b monotherapy dose expansion initiated 19 Killing leukemic stem cells while preserving healthy immune cells 20 LAIR-1 Antibody 11B3* Reduces Tumor Burden in Murine Leukemia Model *11B3: NC525 Murine Parent 02W · Bone marrow blast clearance PERIPHERAL BLOOD 23 ✓ Submitted & cleared IND · Phase 1 monotherapy dose escalation & safety · Biomarkers Powerful, Proven, and Productive Discovery Engine Fuels Our Pipeline Growth · Membrane proteins · Soluble proteins CELL TYPE ...

ext Oure MAY 2023 Treating Cancer by Restoring Immune Function Forward-Looking Statements 2 DIFFERENTIATED PIPELINE Multiple clinical programs, novel targets and diverse indications CAPITAL EFFICIENCY $145.5M balance sheet, runway into mid-2025 QUALITY PRODUCT DEVELOPMENT Fully integrated operations drive innovation, internal manufacturing and capital efficiency the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statem ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38905 NextCure, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38905 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 47-5231247 (State or other ...

Next@ure Next Generation Immunomedicines November 2022 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward- looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements regarding NextCure's expectations, beliefs, i ...